Adam Bonislawski

The spatial omics firm has launched a new platform featuring both high-multiplex and high-throughput options while moving to add RNA measurements.

Seven proteomics firms, ranging from tools companies to diagnostics outfits, listed on public markets in 2021 in a sign of growing interest in the space.

While few if any agents identified by such approaches have made it into widespread clinical practice, several are in various stages of clinical trials.

The agency announced last month that it provided $175 million to seven states and localities to either build, expand, or renovate public health laboratory space.

It has placed the instrument with at least 10 institutions, with researchers using it for purposes including cancer early detection and studies of long COVID.

The company, which closed a $17 million Series A round earlier this month, aims to be able to analyze up to 100,000 samples per quarter by mid-2022.

A pair of recently published papers detail fabricated nanopores with new properties and functionalities suited to various biosensing purposes.

The scientists believe mapping protein forms, including genetic variants and post-translationally modified forms, could drive biology research and tools development.

In a recent study, researchers detailed discovery mass spec workflows that offer high throughput while maintaining stringent standards for protein quantitation.

The company and its early-access users have recently published data from several studies indicating that its platform can boost plasma proteome coverage.